Premium Phosphosite-Specific 7TM Antibodies
Your Resource for GPCR Research
Select Your Country of Delivery below

GPR139 Receptor Antibodies

Close filters
No results were found for the filter!
NEW
Agonist-induced Serine323/Serine324 phosphorylation of the GPR139 Receptor
pS323/pS324-GPR139 (phospho-GPR139 Antibody)
Serine323/Serine324 (S323/S324) is major phosphorylation site of the GPR139 Receptor (GPR139). The pS323/pS324-GPR139 antibody detects phosphorylation in response to agonists. S323/S324 phosphorylation is likely to be involved in...
375.00 € *
Details
NEW
Agonist-induced Threonine315 phosphorylation of the GPR139 Receptor
pT315-GPR139 (phospho-GPR139 Antibody)
Threonine315 (T315) is major phosphorylation site of the GPR139 Receptor (GPR139). The pT315-GPR139 antibody detects phosphorylation in response to agonists. T315 phosphorylation is likely to be involved in efficient ligand sequestration.
375.00 € *
Details
NEW
GPR139 (non-phospho), G protein-coupled Receptor 139 Antibody
GPR139 (non-phospho), G protein-coupled...
The non-phospho-GPR139 receptor antibody is directed against the distal end of the carboxyl-terminal tail of human GPR139. It can be used to detect total GPR139 receptors in Western blots independent of phosphorylation. The GPR139...
375.00 € *
Details

GPR139 (G Protein-Coupled Receptor 139) is an orphan GPCR believed to be activated by L-tryptophan and L-phenylalanine, as well as synthetic agonists. It primarily signals through Gq proteins, influencing intracellular calcium signaling. GPR139 is predominantly expressed in the central nervous system, especially in the habenula, hypothalamus, pituitary, and striatum—regions associated with neuroendocrine function, mood regulation, and reward processing. GPR139 is considered a promising pharmacological target for neurological and psychiatric disorders, including schizophrenia, Parkinson’s disease, addiction, and depression. Its restricted CNS expression and involvement in monoaminergic pathways make it an attractive candidate for drug development. Several selective agonists have been developed in preclinical studies, and research is ongoing to evaluate its therapeutic potential. For more information on GPR139 pharmacology please refer to the IUPHAR database. For further reading refer to:

Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, Pin JP, Spedding M, Harmar AJ. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev. 2013 May 17;65(3):967-86. doi: 10.1124/pr.112.007179. PMID: 23686350; PMCID: PMC3698937.

Alexander SP, Battey J, Benson HE, Benya RV, Bonner TI, Davenport AP, Dhanachandra Singh K, Eguchi S, Harmar A, Holliday N, Jensen RT, Karnik S, Kostenis E, Liew WC, Monaghan AE, Mpamhanga C, Neubig R, Pawson AJ, Pin JP, Sharman JL, Spedding M, Spindel E, Stoddart L, Storjohann L, Thomas WG, Tirupula K, Vanderheyden P. Class A Orphans in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1). Available from: https://doi.org/10.2218/gtopdb/F16/2023.1.

GPR139 (G Protein-Coupled Receptor 139) is an orphan GPCR believed to be activated by L-tryptophan and L-phenylalanine, as well as synthetic agonists. It primarily signals through Gq proteins,... read more »
Close window
GPR139 Receptor Antibodies

GPR139 (G Protein-Coupled Receptor 139) is an orphan GPCR believed to be activated by L-tryptophan and L-phenylalanine, as well as synthetic agonists. It primarily signals through Gq proteins, influencing intracellular calcium signaling. GPR139 is predominantly expressed in the central nervous system, especially in the habenula, hypothalamus, pituitary, and striatum—regions associated with neuroendocrine function, mood regulation, and reward processing. GPR139 is considered a promising pharmacological target for neurological and psychiatric disorders, including schizophrenia, Parkinson’s disease, addiction, and depression. Its restricted CNS expression and involvement in monoaminergic pathways make it an attractive candidate for drug development. Several selective agonists have been developed in preclinical studies, and research is ongoing to evaluate its therapeutic potential. For more information on GPR139 pharmacology please refer to the IUPHAR database. For further reading refer to:

Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, Pin JP, Spedding M, Harmar AJ. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev. 2013 May 17;65(3):967-86. doi: 10.1124/pr.112.007179. PMID: 23686350; PMCID: PMC3698937.

Alexander SP, Battey J, Benson HE, Benya RV, Bonner TI, Davenport AP, Dhanachandra Singh K, Eguchi S, Harmar A, Holliday N, Jensen RT, Karnik S, Kostenis E, Liew WC, Monaghan AE, Mpamhanga C, Neubig R, Pawson AJ, Pin JP, Sharman JL, Spedding M, Spindel E, Stoddart L, Storjohann L, Thomas WG, Tirupula K, Vanderheyden P. Class A Orphans in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1). Available from: https://doi.org/10.2218/gtopdb/F16/2023.1.

Recently viewed